Biotechnology company Pharming Group has revised its full-year 2026 revenue guidance downward to a range of $375 million to $395 million, citing a drop in sales of its flagship product RUCONEST.
The updated forecast represents a $30 million reduction from earlier projections. The company also tightened its expense outlook for the year.
Pharming reported total revenue of $90.2 million for the second quarter of 2026, a 3% decline compared to the same period last year.
The decrease was driven by weakness in RUCONEST, which offset rapid growth in other areas of the business.
RUCONEST Sales Decline
Sales of RUCONEST, a treatment for acute hereditary angioedema attacks, fell 10% year-over-year to $72.3 million in the second quarter.
The company attributed the decline to reduced sales volumes, inventory adjustments among U. S.
pharmacies, and shifting market dynamics in the United States.
Despite the annual drop, RUCONEST sales rebounded 24% from the first quarter of 2026.
Joenja Shows Strong Growth
In contrast, sales of Pharming's other medication, Joenja, surged 40% in the second quarter to $17.9 million.
The growth was driven by an expanding base of paying patients in the U. S.
market.
Pharming's mixed results highlight the challenges of relying on a single product while newer therapies gain traction.
The company continues to focus on expanding its portfolio and commercial reach.
